Associated Papers
Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.
Kavgaci G et al.
Molecular Oncology, 2025
Robust and inducible genome editing via an all-in-one prime editor in human pluripotent stem cells.
Wu Y et al.
Nature Communications, 2024
Molecular characterization of Chinese patients with small bowel adenocarcinoma.
Jin B et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024
Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S et al.
Cancer Medicine, 2024
Correlation between KRAS Mutation and CTLA-4 mRNA Expression in Circulating Tumour Cells: Clinical Implications in Colorectal Cancer.
Aktar S et al.
Genes, 2023
RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status.
Dorard C et al.
Oncogene, 2023
Clinical Significance of Somatic Mutations in RAS/RAF/MAPK Signaling Pathway in Moroccan and North African Colorectal Cancer Patients.
Benmokhtar S et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2022
Complete Screening of Exons 2, 3, and 4 of KRAS and NRAS Genes Reveals a Higher Number of Clinically Relevant Mutations than Food and Drug Administration Quantitative Polymerase Chain Reaction-Based Commercial Kits.
Sánchez-Ibarra HE et al.
Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion, 2020
KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research.
He K et al.
Oncotargets and Therapy, 2020
DNA terminal structure-mediated enzymatic reaction for ultra-sensitive discrimination of single nucleotide variations in circulating cell-free DNA.
Wu T et al.
Nucleic Acids Research, 2018
Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.
Lee B et al.
Oncotarget, 2016
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
Kawazoe A et al.
Bmc Cancer, 2015
Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan.
Hsu KH et al.
Plos One, 2015
A multiplex technology platform for the rapid analysis of clinically actionable genetic alterations and validation for BRAF p.V600E detection in 1549 cytologic and histologic specimens.
Smith DL et al.
Archives of Pathology & Laboratory Medicine, 2014
Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.
Spaans VM et al.
Plos One, 2014
Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.
Bando H et al.
Bmc Cancer, 2013